Abstract: Methods of making 1-methyleffusol are described herein. The 1-methyleffusol compound, and pharmaceutical compositions thereof, can be used to stimulate bone forming activities in a subject in need thereof.

Abstract: Agrimol B (“AGB”) derivatives that contain a sulfone moiety and show improved stability compared to its parent AGB are disclosed. In some forms, the AGB derivatives can possess anticancer properties that are comparable to its parent AGB. Methods for synthesizing the AGB derivatives using a sulfone intermediate or ketone/sulfone intermediate are disclosed. Methods of using the AGB derivatives for treating a cancer, such as large cell lung cancer, in a subject are also disclosed.

Abstract: Platinum (II) complexes (“Pt(II) complexes”) that can emit in the red and/or deep red regions and methods of making and using thereof are described. These Pt(II) complexes can have dinuclearity with close Pt—Pt contact and close interplanar distance, allowing for high emission quantum yield, such as >50%, short emission lifetime, such as <3 ?s, and high radiative decay rate, such as in the order of 105 s?1. The Pt(II) complexes disclosed herein can be included in organic light-emitting devices, such as organic light-emitting diodes (“OLEDs”), for use in commercial applications. OLEDs containing these red-emitting Pt(II) complexes can have current efficiency and/or external quantum efficiency that are comparable or higher than commercially available red emitters and prolonged operational lifetime, such as a LT95 at 1000 nits>9000 h for a red OLED.

Abstract: Compositions and methods for reducing, or inhibiting bone loss in a subject in need thereof have been developed. Pharmaceutical compositions including one or more osteogenic compounds, or functional derivatives thereof, in an effective amount to reduce, or inhibit bone loss, or promote bone formation, preferably via stimulation of osteoblast differentiation, are provided. The compositions are particularly suited for treating bone loss associated with osteoporosis. Methods for treating, or preventing bone loss using the composition, optionally in combination with one or more therapeutic, prophylactic or diagnostic agents, or procedures, are described.

Abstract: Described herein are platinum(II) complexes and their methods of making and using thereof. The design of the platinum(II) complexes results in emission in the blue spectral region with high quantum yields and fast radiative decay rates at room temperature. The platinum(II) complexes can be used to fabricate efficient blue emitting OLEDs.

Abstract: Cyclometalated iron (II) complexes as photothermal transduction agents are described herein. The disclosed complexes show high structural robustness and significant absorption in the near-infrared (NIR) and visible regions. The described complexes can self-assemble to form metallosupramolecular particles, which have excellent photothermal performance and can target tumor by EPR effect. For example, the Fe NPs disclosed herein have strong near-infrared (NIR) absorbance with high photo-heat conversion efficiency of at least 30% (such as about 60%) and/or superior photothermal stability under near-infrared (e.g., 808 nm) laser irradiation. The Fe NPs may be coated with a coating agent, such as bovine serum albumin, to form a coated Fe NPs, which can further enhance the tumor accumulations and biocompatibility of the metallosupramolecular particles in vivo.

Abstract: A highly efficient and atroposelective Rh-catalyzed [2+2+2] cycloaddition for the synthesis of axially chiral aryboron compounds is developed. The reactions of diynes and alkynylborons smoothly occur in an atom-economical manner, affording a variety of C—B atropisomers in excellent yields and enantioselectivities. The protocol features mild conditions, broad substrate scope, and good functional tolerance. The obtained C—B atropisomers show powerful synthetic applications in terms of producing novel chiral phosphine ligands.

Abstract: Platinum (II) complexes (“Pt(II) complexes”) that can emit in the red and/or deep red regions and methods of making and using thereof are described. These Pt(II) complexes can have dinuclearity with close Pt—Pt contact and close interplanar distance, allowing for high emission quantum yield, such as >50%, short emission lifetime, such as <3 ?s, and high radiative decay rate, such as in the order of 105 s?1. The Pt(II) complexes disclosed herein can be included in organic light-emitting devices, such as organic light-emitting diodes (“OLEDs”), for use in commercial applications. OLEDs containing these red-emitting Pt(II) complexes can have current efficiency and/or external quantum efficiency that are comparable or higher than commercially available red emitters and prolonged operational lifetime, such as a LT95 at 1000 nits>9000 h for a red OLED.

Abstract: Described herein is an iron(II)-phthalocyanine catalyzed C—H bond amination of alkyl azides. The catalyst is effective to produce intramolecular amination of saturated C—H bonds in moderate to excellent yields and the methods are tolerant of a wide scope of substrates. The methods described are useful for the synthesis of natural products derivatives and for the late-stage functionalization of pharmaceuticals.

Abstract: Described herein are dinuclear platinum(II) emitter complexes and their methods of making and using thereof. The design of the dinuclear platinum(II) emitters results in short radiative lifetimes and high quantum yields. The dinuclear platinum(II) emitter complexes can be used to fabricate blue emitting OLEDs.

Abstract: Described herein are compounds containing palladium(II), as the central metal atom, and tetradentate [N{circumflex over (?)}C{circumflex over (?)}C{circumflex over (?)}N] ligands. The compounds are charge neutral, and feature a donor-acceptor structure where a pendant substituted amino group (such as unsubstituted diphenylamine or substituted diphenylamine) and a heteroaryl group (such as pyridine group) serve as donor and acceptor, respectively. This donor-acceptor structure introduces a set of low-energy singlet and triplet charge-transfer excited states with small energy separation allowing for efficient thermally activated delayed fluorescence to take place.

Abstract: Described are multi-resonance-thermally-activated delay-fluorescence compounds containing (i) a polycyclic aromatic/heteroaromatic ligand in which a plurality aromatic/heteroaromatic rings are linked by boron and nitrogen atoms and (ii) an N-heterocyclic carbene ligand, with both ligands coordinated to a metal atom/ion that has a high spin-orbit coupling. The use of the high spin-orbit coupling of metals and/or metal ions facilitates the intersystem crossing and/or reversed intersystem crossing processes of MR-TADF emitters, thereby largely accelerating the rate of TADF and substantially shortening the lifetime of deleterious triplet excitons. The MR-TADF emitters can be used to fabricate blue to green emitting OLEDs.

Abstract: Described herein are dinuclear platinum(II) complexes and their methods of making and using thereof. The design of the dinuclear platinum(II) complexes results in red to deep-red photoluminescence with high quantum yields at room temperature, short emission lifetimes, and fast radiative decay rates. The dinuclear platinum(II) complexes can be used to fabricate red and/or NIR emitting OLEDs.

Abstract: Described herein are dinuclear platinum(II) emitter complexes and their methods of making and using thereof. The design of the dinuclear platinum(II) emitters results in short radiative lifetimes and high quantum yields. The dinuclear platinum(II) emitter complexes can be used to fabricate blue emitting OLEDs.

Abstract: Disclosed are stable, high-efficiency voltage-dependent color-tunable organic light-emitting diodes with a single emitter, such as tetradentate platinum (II) complex, having long operational lifetime. High-performance voltage-dependent color-tunable OLEDs with a single Pt [O{circumflex over (?)}N{circumflex over (?)}C{circumflex over (?)}N] emitter are fabricated. The emission color can be tuned from warm white to nature white or from orange to yellowish green upon the emitter used. Long-term operational stability and continuously variable color enable these color-tunable OLEDs to find applications in smart wearable devices.

Abstract: A nontoxic anticancer compound is a derivative of 20-O-?-(D-glucopyranosyl)-20(S)-protopanaxadiol (CK) having at least one of the glucose hydroxyl groups replaced with at least one acetal group. The derivative enhances binding to a mitochondrial membrane protein and is more cytotoxic to cancerous cells than CK. The derivative can be an acetal of an unsubstituted or substituted aromatic group, such as an acetal formed from a substituted 1-(dimethoxymethyl)-benzene. One or more of the CK derivative (CKD) anticancer compounds can be used as an active portion of an anticancer medicament.

Abstract: Compositions and methods for reducing, or inhibiting bone loss in a subject in need thereof have been developed. Pharmaceutical compositions including one or more osteogenic compounds, or functional derivatives thereof, in an effective amount to reduce, or inhibit bone loss, or promote bone formation, preferably via stimulation of osteoblast differentiation, are provided. The compositions are particularly suited for treating bone loss associated with osteoporosis. Methods for treating, or preventing bone loss using the composition, optionally in combination with one or more therapeutic, prophylactic or diagnostic agents, or procedures, are described.

Abstract: Described herein is an iron(II)-phthalocyanine catalyzed C—H bond amination of alkyl azides. The catalyst is effective to produce intramolecular amination of saturated C—H bonds in moderate to excellent yields and the methods are tolerant of a wide scope of substrates. The methods described are useful for the synthesis of natural products derivatives and for the late-stage functionalization of pharmaceuticals.

Abstract: Gold(III) emitters showing high emission quantum efficiency and stable in thermal deposition process are described. High performance OLEDs can be fabricated from these emitters.

Abstract: Gold(III) emitters showing high emission quantum efficiency and stable in thermal deposition process are described. High performance OLEDs can be fabricated from these emitters.